Simon James Harrison

49PUBLICATIONS
242CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsHaematological tumoursImmunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Sep 30, 2026
Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

|Sep 16, 2026
Toxicity-Related Treatment Cessation in Newly Diagnosed Multiple Myeloma-Risk Factors and Survival: An Analysis From the APAC and ANZ Myeloma and Related Diseases Registry.

|Sep 16, 2026
T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

|Sep 07, 2026
Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.

|Jul 22, 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

|May 30, 2026
Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Pageof 9

Frequent Collaborators

7 joint publications

Mark R Dowling

6 joint publications

Andrew Spencer

6 joint publications

Michael J Dickinson

5 joint publications

Benjamin W Teh